Patient Profile: Newly diagnosed Type 1 diabetic enrolled with an A1c of 16.9%
Medications/Supplies:
- Dexcom™ continuous glucose monitoring (CGM) system
- Valsartan™
- Humalog Insulin Lispro™
- Tresiba™
- Rosuvastatin
Northwind Actions: Comprehensive support and proactive coordination led to rapid and sustained glycemic control
NW Measures Taken:
- 12 pharmacist consultations
- Medication optimization including statin and ARB therapy
- Coordinated with provider after patient missed 2 appointments
- Prompted and ensured foot and eye exams were completed
Clinical Results:
- A1c trend: A1c trend: 8.8% Reduction in 5 months
- Upon program engagement in June 2023, hemoglobin A1c was 16.9%. Patient’s A1c dropped to 6.7% in November 2023 and has remained stable to date.
- Maintained A1c around 7.0 for over a year